ALKS · Alkermes plc.
Market Cap
$7.72B
Shares
167.76M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$43.39
Open$46.51
Day$43.27–46.53
52W close$27.13–55.22
Avg vol 30d1.6M
Short int14.7M · 8.8% float · 11.8d
Short vol60%
Last earningsJul 28, 2026
DataJan 2020–Sep 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 21, 2026
Est · unconfirmed
· in 4 wks
filed Jul 28, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.67B
Trailing 12 months
Net income (TTM)
$66.12M
Trailing 12 months
Revenue growth YoY
+27.0%
Year over year
Operating margin
7.0%
Trailing 12 months
P / E (TTM)
114.2
Trailing earnings · reciprocal yield 0.9%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.0%
Year over year · more shares
Price change (1Y)
+52.0%
Trailing year
Short interest
8.8%
Latest settlement · 11.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Moderate
Market backdrop
VIX 14.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+13%
above
Price vs 50-day avg
−12%
below
RSI (14)
30
oversold
MACD trend
Negative
52-week position
58%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
+48%
trailing
YTD return
+55%
this year
Relative strength
+28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $49 › 200d $38 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +90 funds added
Insider flow
Distributing
Net -$2.2M over 90 days · 100% sells
Short interest
Falling
8.77% of float · ▼ -0.3% MoM · 11.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
424 holders — near 3-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
−5%
Y/Y
EPS growth
−34%
Y/Y
Free cash flow
$480.3M
Valuation
P/E 121.1
rich
Buyback
$172.3M
remaining
Balance sheet
$388.6M
net cash
Quant / Vol
risk profile
Volatility
41%
annualized · 1-yr
Max drawdown
−22%
past year
ATR
3.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jul 28, 2026
2026
Vivitrol net sales
$460M – $480M
Q3
Total net sales from the four proprietary products
$390M – $410M
Cost of goods sold
$85M – $95M
Total revenues
$450M – $470M
generally similar to Q2 levels in the range of $390 to $410 mill
Net sales from the four proprietary products
$390M – $410M
third quarter
Costs
$85M – $95M
R&D expenses
$120M – $130M
SG&A expense
$215M – $225M
Adjusted EBITDA
$80M – $100M
for the year
EBITDA
$75M – $95M
Prior guidance
period ended
· from the 8-K filed Jul 24, 2024
Effective Tax Rate
· Year Ending Dec. 31, 2024
17%
VIVITROL® net sales
· Year Ending Dec. 31, 2024
$410M – $430M
ARISTADA® net sales
· Year Ending Dec. 31, 2024
$340M – $360M
LYBALVI® net sales
· Year Ending Dec. 31, 2024
$275M – $295M
Guided vs delivered
· last 2 settled
Total revenues
full year 2021
guided $1.15B – $1.19B
$1.17B
In line
Total revenues
2020
guided $1.01B – $1.04B
$1.04B
Beat +1.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+13%
Bullish
Price vs 50-day avg
−12%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
58%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $49 › 200d $38 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +90 funds added
Insider flow
Distributing
Net -$2.2M over 90 days · 100% sells
Short interest
Falling
8.77% of float · ▼ -0.3% MoM · 11.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
424 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $27
Now $43 · 58%
Range high $55
vs 200-day avg +13%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Alixorexton external R&D expenses | $28.8M | Three Months Ended June 30, 2026 filing | +21.0% |
|
|
|||
| ARISTADA and ARISTADA INITIO product sales, net | $96.7M | Three Months Ended June 30, 2026 filing | -4.5% |
|
|
|||
| Long-acting INVEGA products manufacturing and royalty revenues | $27.4M | Three Months Ended June 30, 2026 filing | — |
| LUMRYZ external R&D expenses | $4.7M | Three Months Ended June 30, 2026 filing | — |
|
|
|||
| LUMRYZ product sales, net | $96.6M | Three Months Ended June 30, 2026 filing | — |
|
|
|||
| LYBALVI product sales, net | $93.9M | Three Months Ended June 30, 2026 filing | — |
| Other manufacturing and royalty revenues | $26.3M | Three Months Ended June 30, 2026 filing | — |
| VIVITROL product sales, net | $124.5M | Three Months Ended June 30, 2026 filing | +2.3% |
|
|
|||
| VUMERITY manufacturing and royalty revenues | $30.6M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALKS
this stock
Alkermes plc.
|
$7.72B | +55.1% | -5.2% | 121.1 | 8.8% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.39B | +21.3% | — | — | 0.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.42B | +24.9% | +4.3% | 63.9 | 3.2% |
|
GALDY
Galderma Group AG/ADR
|
$44.48B | -7.1% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALKS | -5.6% | -9.6% | +47.6% | -7.7% | +55.1% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | -5.3% | -9.5% | +27.5% | -7.0% | +43.4% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$400.00M
Spent (derived)
$227.70M
Remaining
$172.30M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.